Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | p450 reductase, putative | 0.0085 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0085 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0085 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0085 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0085 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0085 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0075 | 0.7743 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0052 | 0.2407 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0085 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0042 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0085 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0085 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0085 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0085 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0085 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0085 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0085 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0085 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0085 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0042 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0075 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0085 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0085 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0043 | 0.0151 | 0.0151 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0085 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0052 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0085 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0085 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 25.9185 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.